Xenothera

Xenothera company information, Employees & Contact Information

Updated May 2026

Quick answer

Xenothera is a Biotechnology Research company and founded in 2014. It has approximately 25 employees on record. Contact data was last refreshed in May 2026. Find Xenothera's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

XENOTHERA is a biotechnology company based 21 rue La Nouë Bras de Fer, 44000 Nantes, France.

Company Details

Employees
25
Founded
2014
Address
1 Rue Vauban, Nantes,france 44000,france
Phone
33240412987
Email
co****@****era.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Nantes, France
Looking for a particular Xenothera employee's phone or email?

Xenothera Questions

News

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants - Frontiers

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants Frontiers

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2 - Wiley Online Library

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2 Wiley Online Library

ESSA Pharma (EPIX) Shareholders Approve Acquisition by XenoThera - GuruFocus

ESSA Pharma (EPIX) Shareholders Approve Acquisition by XenoThera GuruFocus

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19 - Frontiers

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19 Frontiers

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial - BioMed Central

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial BioMed Central

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants - Frontiers

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants Frontiers

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation - Frontiers

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation Frontiers

Top Xenothera Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant